RSS

T-cell therapy

Singapore-based biotech company, Lion TCR, has received approval from the Health Services Authority (HSA) of Singapore for its Phase I/II multicentre clinical study of its T cell engineered immunotherapy for the treatment of liver cancer. Read more

News

Cell & Gene Therapies: A guide to single-use fluid connections Read more

A recently published preliminary study involving primates has revealed that a form of engineered stem cell-derived chimeric antigen receptor (CAR) T-cells may be useful in the long-term suppression of HIV. Read more

News

Edison Investment Research, has released an independent and detailed analyst report into T-cell cancer therapies, highlighting the potential and limitations of current CAR-T approaches for most tumour types. Read more

Analysis